8-K: PROCEPT BioRobotics Charts Path to Profitability, Cancer Market

PROCEPT BioRobotics outlines strong financial growth, margin expansion, and a clear path to profitability by 2027, alongside strategic expansion into the prostate cancer market.

Summary

• PROCEPT BioRobotics Corporation (PRCT) hosted an Investor Day on February 26, 2026, detailing its strategy to accelerate procedure growth, drive profitability, and advance innovation.
• The company provided 2026 revenue guidance of $390 million to $410 million, representing 27% to 33% year-over-year growth, and projected 25% to 30% annual revenue growth for 2027.
• Gross margin is expected to expand to 65% in 2026, targeting a range of 68% to 70% in 2027.
• Adjusted EBITDA loss is guided to significantly narrow to between $30 million and $17 million in 2026, with a projected gain of $25 million to $30 million in 2027, achieving positive EBITDA in Q4 2026.
• Worldwide Aquablation procedures are projected to reach 60,000 to 64,000 in 2026, up from 43,300 in 2025.
• The global install base for Aquablation systems grew to over 900 by 2025, with Category I Reimbursement established as of January 1, 2026.
• The company is launching its next-generation AI-enabled robotic platform, HYDROS, which is expected to represent the majority of the install base by the end of 2026.
• PROCEPT BioRobotics is strategically expanding into the prostate cancer treatment market, with ongoing clinical trials (WATER IV) comparing Aquablation to radical prostatectomy.
• Early data from the Endeavor Health Series showed Aquablation significantly slowed cancer progression, with 44% fewer upgrades at 5 years compared to active surveillance.
• The PRCT001 study indicated stable erectile function and low urinary incontinence rates through 12 months for prostate cancer patients treated with Aquablation.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive update, driven by robust financial guidance indicating strong revenue growth, significant margin expansion, and a clear path to profitability. The strategic expansion into prostate cancer treatment with promising early clinical data further enhances long-term growth prospects.

Positives

• Strong revenue growth guidance: $390M-$410M for 2026 (27-33% growth) and 25-30% annual growth for 2027.
• Clear path to profitability: Adjusted EBITDA gain of $25M-$30M projected for 2027, with positive EBITDA expected in Q4 2026.
• Significant gross margin expansion: 65% guided for 2026, targeting 68-70% in 2027, driven by handpiece pricing discipline and mix.
• Aquablation is trending towards becoming the leading modern surgical BPH treatment, with over 125,000 worldwide procedures completed by 2025.
• Introduction of the HYDROS Robotic System, an AI-enabled platform designed for scalable adoption and expected to be the majority of the install base by end of 2026.
• Strategic expansion into the prostate cancer market, a significant adjacency, with ongoing pivotal clinical trials (WATER IV) and promising early data.
• Clinical evidence supports Aquablation's efficacy for BPH, offering complete symptom relief and preserved sexual/urinary function with low re-operation rates.
• Dedicated launch teams have reduced time from purchase order to first ten cases by approximately 50% in pilot accounts in Q4 2025.
• Strong balance sheet with no expectation for cash balance to drop below $175 million and a manageable $52 million bank loan maturing in Q4 2027.
• R&D spend is expected to leverage, with revenue growth outpacing R&D, targeting 15-17% of sales long-term.

Negatives

• The BPH market remains significantly undertreated, with many patients fearing procedures and Aquablation having low unaided patient awareness (1-2%).
• Surgeon comfort with legacy procedures presents a challenge for broader adoption of Aquablation.
• The company anticipates tariff exposure from a Chinese ultrasound supplier of $5M-$6M in 2026 and approximately $6M in 2027, though mitigation strategies are in place.
• Despite significant improvement, the company is still projected to incur an Adjusted EBITDA loss in 2026.

Risks

• The rate and degree of market acceptance of the AQUABEAM and HYDROS Robotic Systems and Aquablation therapy may not meet expectations.
• The establishment and maintenance of consistent and favorable payment policies for Aquablation therapy are crucial for continued growth.
• The company's ability to manage the anticipated growth of its commercial sales and marketing organization is a factor.
• Volumes of elective procedures performed by health care providers and hospital medical device budgets could impact results.
• Increased competition and innovations by new and existing competitors in the market for competitive treatments pose a risk.
• Obtaining required regulatory approvals and clearances to market and sell products in certain other countries may be challenging.
• The development and protection of future innovation, including intellectual property rights, is critical.
• Dependence on a limited number of third-party suppliers for components of products could lead to supply chain disruptions.
• The successful completion of clinical trials, particularly for new indications like prostate cancer, is not guaranteed.
• The adoption of the company's technology for expanding or additional indications may not occur as anticipated.
• Aquablation therapy for prostate cancer is currently limited by federal law to investigational use only, and its safety and effectiveness have not been established.

Future Outlook

PROCEPT BioRobotics anticipates achieving positive Adjusted EBITDA in Q4 2026, leading to a full-year Adjusted EBITDA gain of $25 million to $30 million in 2027. The company projects continued strong revenue growth of 25% to 30% in 2027 and aims for gross margins of 68% to 70%. The HYDROS system is expected to dominate the install base by the end of 2026, with global expansion underway. The company is committed to advancing its prostate cancer program, with the WATER IV pivotal trial expected to complete procedures by mid-2026, aiming to establish Aquablation as a frontline option.

Management Comments

• Larry L Wood (CEO): "We are now moving from establishing Aquablation as a therapy to leading BPH treatment."
• Larry L Wood (CEO): "Aquablation is ready to move to the standard of care."
• Pooja Sharma Rao (CMO): "We believe this is an important inflection point."
• Pooja Sharma Rao (CMO): "The engine around BPH lays a foundation on which we can launch a prostate cancer application."
• Barry Templin (CTO): "Prostate cancer is not a focal disease, and focal treatment is limited."
• Barry Templin (CTO): "We believe Aquablation will play a meaningful role in the treatment of prostate cancer."
• Barry Templin (CTO): "We are the First Company to receive FDA-IDE approval to enroll a randomized trial comparing surgical therapy vs. radical prostatectomy."
• Kevin Waters (CFO): "Strong track record of driving growth, expanding margins and scaling efficiently."
• Kevin Waters (CFO): "Aquablation remains significantly underpenetrated in the U.S."

Industry Context

StockSavvy.ai notes that PROCEPT BioRobotics is strategically positioning Aquablation as a comprehensive solution for BPH, addressing patient desires for symptom relief, sexual function preservation, and single-procedure efficacy, which contrasts with the stepwise, less invasive approach often taken by physicians. The company's expansion into prostate cancer treatment, particularly with its AI-enabled HYDROS platform and ongoing WATER IV trial, aligns with a broader industry trend towards less invasive, more precise surgical interventions and personalized medicine, potentially disrupting traditional treatments like radical prostatectomy.

Comparison to Industry Standards

• Aquablation is trending towards becoming the leading modern surgical BPH treatment, closing the gap with TURP and becoming the leading resective BPH treatment second only to TURP.
• Compared to other BPH treatments (Rezum, Urolift, Enucleation, Greenlight, Simple Prostatectomy), Aquablation shows strong growth in procedure volume.
• Aquablation offers a "complete solution" for BPH across all prostate sizes, prioritizing symptom relief and sexual/continence preservation, unlike non-resective or some resective methods.
• Re-operation rates for Aquablation are shown to be significantly lower than UroLift, Rezum, PAE, PVP, and comparable to HoLEP and Simple Prostatectomy over time (Rubin B, et al. AUA 2025 data).
• In prostate cancer, the PRCT001 study showed Aquablation patients had stable erectile function and low urinary incontinence rates through 12 months, contrasting favorably with published data for Radical Prostatectomy (PROTECT STUDY, AFU STUDY, TrueNTH STUDY).
• The Endeavor Health Series study indicated Aquablation significantly slowed cancer progression, with 44% fewer upgrades at 5 years compared to active surveillance.

Stakeholder Impact

• Shareholders: Potential for significant value appreciation due to strong financial guidance, clear path to profitability, and expansion into a large, new market (prostate cancer).
• Patients (BPH): Improved access to a comprehensive and effective treatment option (Aquablation) that offers complete symptom relief while preserving sexual and urinary function, with lower re-operation rates.
• Patients (Prostate Cancer): Potential for a new, less invasive treatment option that offers whole gland resection while sparing critical anatomy, with promising early data on stable erectile function and low incontinence rates.
• Healthcare Providers/Hospitals: Streamlined adoption and training for the HYDROS system through dedicated launch teams, potentially increasing procedure volumes and improving patient outcomes.
• Employees: Growth and expansion into new markets and product lines could lead to increased opportunities and job security.

Next Steps

• Accelerate procedure growth for BPH through commercial execution, including incentivizing organic growth, activating New Account Launch Teams, and maintaining handpiece pricing discipline.
• Drive path to profitability through improved operating leverage, expanding gross margins, and disciplined R&D spend.
• Advance evidence and innovation for both BPH and prostate cancer, including the global expansion of the HYDROS system.
• Complete all WATER IV clinical trial procedures for prostate cancer by mid-2026.
• Educate patients that waiting isn't winning for BPH, starting with those considering alternative surgical options and expanding to dissatisfied medically managed patients.
• Work with suppliers to onshore manufacturing to mitigate tariff exposure, with stabilization expected in 2027.
• Continue to drive working capital improvements to enhance financial efficiency.

Key Dates

Recommendation

The company has provided robust financial guidance indicating accelerated revenue growth, significant gross margin expansion, and a definitive timeline to achieve profitability by 2027, with positive EBITDA expected in Q4 2026. The strategic expansion into the large prostate cancer market, supported by promising early clinical data and a methodical development plan, represents a substantial long-term growth driver. These factors, combined with a strong balance sheet and operational efficiencies, position PROCEPT BioRobotics for significant future value creation, making it a compelling investment opportunity.

Keywords

PROCEPT BioRobotics, PRCT, Aquablation, BPH treatment, Benign Prostatic Hyperplasia, Prostate Cancer, HYDROS Robotic System, Robotics, Medical Devices, Urology, Surgical Procedures, Financial Guidance, EBITDA, Gross Margin, Investor Day, Clinical Trials, WATER IV